



## **Cerulean Pharma Inc. Appoints Chief Medical Officer**

*Edward Garmey, M.D., to serve as Chief Medical Officer  
and Senior Vice President*

CAMBRIDGE, Mass. – May 17, 2011 – [Cerulean Pharma Inc.](#), a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the appointment of Edward Garmey, M.D., to serve as Chief Medical Officer and Senior Vice President. Dr. Garmey will succeed Dr. John Ryan, who has been named Chairman of the Company's Medical Advisory Board.

Prior to his appointment at Cerulean, Dr. Garmey served as Vice President for Clinical Development at ArQule, Inc., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib), in different cancer types including non-small cell lung cancer. While at ArQule, Dr. Garmey also served as clinical development liaison with external development partners in the U.S., Europe, and Japan. Prior to joining ArQule, Dr. Garmey was Medical Director at GPC Biotech, where he was involved in overseeing global clinical development studies in oncology.

A pediatric hematologist-oncologist by training, Dr. Garmey holds an A.B. from Harvard University and an M.D. from the Mount Sinai School of Medicine. He completed his residency training at the Tulane University School of Medicine as well as several clinical and research fellowships at institutions including the Children's Hospital of Los Angeles, Memorial Sloan-Kettering Cancer Center, the National Institutes of Health, and the Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana.

"We are thrilled to have Edward join Cerulean," said Oliver Fetzer, Ph.D., President and CEO of Cerulean. "He brings to the Company a tremendous background in oncology clinical development, especially in non-small cell lung cancer. It is a particularly exciting time to have Edward come on board as we initiate our Phase 2 trial for CRLX101, our lead nanopharmaceutical clinical development candidate. I also want to thank John for his extraordinary contributions during the last two years, and I look forward to continuing our relationship with him as Medical Advisor."

### **About CRLX101**

CRLX101 is a tumor-targeted nanopharmaceutical designed to inhibit topoisomerase 1 and hypoxia-inducible factor-1 alpha (HIF-1 $\alpha$ ). CRLX101 is also designed to concentrate drug in tumor tissue and tumor cells, prolonging drug exposure at the site of action. CRLX101 is currently in Phase 2 development. More information on CRLX101 clinical studies can be found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

**About Cerulean Pharma Inc.**

Cerulean Pharma Inc. is a clinical-stage company specializing in the design and development of tumor-targeted nanopharmaceuticals. Cerulean is applying its proprietary nanopharmaceutical platform technologies and specialized capabilities to advance a new class of therapeutic agents for diseases with unmet medical needs. With an initial focus in oncology, the Company's technology platform can be readily applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. Cerulean is privately financed and funded by experienced healthcare investors, including Polaris Venture Partners, Venrock, Lilly Ventures, Lux Capital, Bessemer Venture Partners, Alexandria Real Estate Equities, and William H. Rastetter. Cerulean is located in Cambridge, Massachusetts. For more information, please visit the Company's website at <http://www.ceruleanrx.com>.

# # #

**Media Contacts:**

Schwartz Communications

Andrew Law/Benjamin Navon

[cerulean@schwartzcomm.com](mailto:cerulean@schwartzcomm.com)

+1 781-684-0770